Proven Predictivity of Cardiosafety
Leading pharmaceutical companies have used Vala’s KIC/CyteSeer assays to inform cardiotoxity decision-making across multiple disease areas. Vala screening data has proven highly predictive in determining which compounds should move forward during lead series development.
High Throughput, Big Data Assessment of Complex Arrhythmia Waveforms
Other technology platforms currently used by the industry for in vitro cardiosafety assessment of contractility and action potentials in hiPSC-cardiomyocytes cannot detect the full complexity of arrhythmia waveforms exhibited by ex vivo models. Meanwhile, ex vivo models are laborious and can be performed at only relatively low throughputs. Only Vala’s single-cell big data assessments can produce the multi-channel data needed to judge cardiosafety. This process is limited today only by the manual nature of the data analysis performed by the Vala team.
Expanding Capacity and Understanding with Artificial Intelligence
Early studies utilizing Vala’s ValaDATE™ AI platform have demonstrated the ability to automate the identification and analysis of more complex arrhythmia patterns with 95% accuracy. As this capability expands, Vala hopes to provide further insights into the underlying mechanisms of cardiotoxicity.